Clinical trials
Systemic Sclerosis (SSc) clinical trials
Below are recruiting systemic sclerosis (ssc) clinical trials, each written for real people, not researchers. We’re tracking 99 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06375005RecruitingPhase 2
Telitacicept for early diffuse scleroderma
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Yangzhou, JiangsuAges 18–70 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT04986605RecruitingPhase 2
Photopheresis for early diffuse scleroderma
This trial tests a treatment called extracorporeal photopheresis (ECP) for people with early diffuse systemic sclerosis (scleroderma). ECP is a procedure where your blood is treated with light and a medication, then returned to your body, and it may help reduce skin thickening and other symptoms.
London, OntarioAges 18 years+ - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07188285Enrolling by invitation
Immune system study for active autoimmune diseases
This study uses a blood test called mass spectrometry to look at the immune system in people with active autoimmune diseases. It aims to find patterns that could help doctors better understand and treat these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06954597RecruitingPhase 2
Testing a new cream for scleroderma finger ulcers
This study tests a new cream (TOP-N53) for digital ulcers caused by scleroderma. The cream is applied directly to the sore, and the goal is to see if it is safe and helps the ulcer heal.
BordeauxAges 18 years+ - NCT05098704RecruitingPhase 2/Phase 3
Clopidogrel to help prevent systemic sclerosis in high-risk people
This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.
BayonneAges 18–85 - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT07245238RecruitingPhase 3
CBD lotion for itching in scleroderma
This trial tests if a CBD (cannabidiol) lotion can help reduce itching in people with scleroderma, a condition that often causes chronic itch. It compares the CBD lotion to a placebo (inactive lotion) to see if it works and is safe.
Khon KaenAges 18–70 - NCT07228429Recruiting
Measuring calcium deposits in scleroderma with CT scans
This study will use CT scans to measure calcium deposits under the skin in people with scleroderma. It may help doctors better understand and track this condition.
New Haven, ConnecticutAges 18 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07182981Recruiting
Chewing and swallowing in scleroderma patients
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
Çankaya, AnkaraAges 7 years+ - NCT07183072Recruiting
Scleroderma: Physical Performance and Functionality Study
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
Çankaya, AnkaraAges 7 years+ - NCT07167537RecruitingPhase 1
Study of OL-CD19-GDT for hard-to-treat autoimmune diseases
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
BeijingAges 18–65 - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT06894654Recruiting
Identifying skin regulation in scleroderma
This study compares skin samples from people with scleroderma and healthy volunteers to understand what goes wrong in the skin. It may help researchers find new treatment targets.
LeedsAges 18 years+ - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Los Angeles, CaliforniaAges 18 years+ - NCT06672822RecruitingPhase 2
STS injections for calcinosis in scleroderma
This trial tests if injecting a medication called STS directly into calcium deposits can relieve pain and symptoms. It may help patients with scleroderma or related conditions who have painful calcium lumps.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis (ssc)?
- Yes. Clin2 currently lists 99 recruiting systemic sclerosis (ssc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis (ssc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis (ssc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.